ArticleScientific reports2017
Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- New insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis.PloS one · 2025Pooled it
- Pooling analysis reveals that galectin-1 is a reliable prognostic biomarker in various cancers.Journal of cellular physiology · 2019Pooled it
- Diagnostic Performance of Galectin-1 and Mucin-1 in Uterine Tumors: A Case-Control Study.Current issues in molecular biology · 2026Article
- Clinical utility of GAL-8, ITGΒ-1, and HIF-1α as non-invasive diagnostic and prognostic biomarkers for assessing glioma.Journal of neuro-oncology · 2025Article
- Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.International journal of molecular sciences · 2025Review
- Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer.ACS pharmacology & translational science · 2025Article
- The Sweet Side of IVF: Biological Role and Diagnostic Potential of Galectin-9 in Female Infertility.International journal of molecular sciences · 2025Article
- "Galectin-9: A double-edged sword in Acute Myeloid Leukemia".Annals of hematology · 2025Review
- Development of Galectin-7-Specific Nanobodies: Implications for Immunotherapy and Molecular Imaging in Cancer.Journal of medicinal chemistry · 2025Article
- Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy.Molecular cancer therapeutics · 2025Review
- Identification of Molecular Subtypes Associated with PCD in Esophageal Squamous Cell Carcinoma and Analysis of Immune Microenvironment.Current medicinal chemistry · 2025Article
- Galectin-8 Contributes to Human Trophoblast Cell Invasion.International journal of molecular sciences · 2024Article
- The role of galectins in the regulation of autophagy and inflammasome in host immunity.Seminars in immunopathology · 2024Review
- Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer.International journal of molecular sciences · 2024Article
- Hypoxia-induced galectin-8 maintains stemness in glioma stem cells via autophagy regulation.Neuro-oncology · 2024Article
- Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- The role of galectins in mediating the adhesion of circulating cells to vascular endothelium.Frontiers in immunology · 2024Review
- Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectins are moving closer to center stage in detecting glycosylation aberration in cancer cells. Here, we have investigated the expression of galectins in ovarian cancer (OC) and examined their potential as biomarkers in tissues and blood plasma samples of high grade serous ovarian carcinoma (HGSC) patients. In tissues, we found that increased protein expression of stromal gal-1 and epithelial gal-8/9 was associated with a poor response to treatment of HGSC patients. Gal-8/9 were both independent predictors of chemoresistance and overall survival (OS), respectively. This galectin signature increased the predictive value of the cancer antigen 125 (CA125) on 5-year disease-free survival (DFS), post-chemotherapy treatment and 5-year OS. In CA125
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.